证券日报网讯华神科技（000790）8月12日在互动平台回答投资者提问时表示，公司子公司华神生物公 司拥有国家一类新药利卡汀(碘[131I]美妥昔单抗注射液)产品，主要用于不能手术切除或术后复发的原 发性肝癌，以及不适宜作动脉导管化学栓塞(TACE)或经TACE治疗后无效、复发的晚期肝癌患者。 ...

证券日报网讯华神科技（000790）8月12日在互动平台回答投资者提问时表示，目前公司子公司华神钢 构暂未参与西藏扎曲果多水电站建设项目。 ...

Core Viewpoint - Huasheng Technology (000790) emphasizes the prescription nature of its product, Sanqi Tongshu Capsule, and acknowledges the need for improved channel layout and refined operations in specific markets [1] Group 1: Market Strategy - The company plans to enhance market expansion efforts and improve product accessibility in key cities across the country [1] - Ongoing initiatives include strengthening supply chain collaboration and optimizing resource allocation dynamically [1] Group 2: Operational Focus - The company recognizes the potential for improvement in channel management and operational efficiency [1] - Continuous efforts are being made to refine channel management practices [1]

证券日报网讯华神科技（000790）8月12日在互动平台回答投资者提问时表示，公司子公司海南华神星 瑞药业科技有限公司作为公司医药大健康产业布局的组成部分，公司将持续深耕医药大健康产业。 ...

每经AI快讯，有投资者在投资者互动平台提问：公司是否有护牙的漱口瓶装水卖吗？ 华神科技（000790.SZ）8月12日在投资者互动平台表示，公司暂无上述产品。 （文章来源：每日经济新闻） ...

每经AI快讯，有投资者在投资者互动平台提问：公司子公司成都华神生物技术有限责任公司生产的国 家一类新药——碘[131I>美妥昔单抗注射液（利卡汀）是公司自研的吗？主要针对那些疾病？ 华神科技（000790.SZ）8月12日在投资者互动平台表示，公司子公司华神生物公司拥有国家一类新药利 卡汀（碘[131I]美妥昔单抗注射液）产品，主要用于不能手术切除或术后复发的原发性肝癌，以及不适 宜作动脉导管化学栓塞（TACE）或经TACE治疗后无效、复发的晚期肝癌患者。 （文章来源：每日经济新闻） ...

Core Viewpoint - Huasheng Technology has shifted its focus to the pharmaceutical sector while announcing the divestiture of its pharmaceutical distribution subsidiary, indicating a strategic realignment to enhance core business capabilities and profitability [2][3][4]. Group 1: Divestiture Details - Huasheng Technology plans to publicly transfer 51% of its stake in Tibet Kangyu Pharmaceutical Co., Ltd. at a base price of 63.78 million yuan [2][4]. - The company acquired this stake for 51 million yuan in August 2023, with performance guarantees tied to net profit targets for the subsequent years [2][6]. - The decision to sell comes before the end of the performance guarantee period, raising questions about the subsidiary's financial health [2][7]. Group 2: Financial Performance - In 2023, Huasheng Technology reported revenue of approximately 1 billion yuan, a year-on-year increase of 14.92%, with the pharmaceutical segment contributing about 511 million yuan, up 21.17% [6][9]. - However, in 2024, Tibet Kangyu failed to meet its profit commitments, achieving only 1.68 million yuan in net profit, representing a completion rate of 83.92% [7][8]. - The company's net profit has been declining, with a drop of 32.89% in 2023 and a projected loss of 45 to 55 million yuan in the first half of 2025 [9][11]. Group 3: Strategic Implications - The divestiture is part of a broader strategy to concentrate resources on core business areas, aiming to improve profitability and competitive strength [3][4]. - The sale will remove Tibet Kangyu's distribution business from Huasheng's consolidated financial statements, although the company's own product distribution will continue to be managed internally [9]. - The shift in revenue structure shows a significant increase in the pharmaceutical business's contribution to total revenue, rising from 48.33% to 73.74% over three years [9].

Core Viewpoint - Huasun Technology's acquisition strategy has turned into a burden, leading to a continuous decline in profitability, with significant losses expected in the near future [1][8]. Group 1: Acquisition and Performance Issues - Huasun Technology plans to transfer 51% of its subsidiary, Tibet Kangyu, for a base price of 63.78 million yuan, after acquiring it for 51 million yuan just two years prior [2][3]. - The acquisition of Tibet Kangyu and Yuanhong Mineral Water, totaling 84.2 million yuan, has not met performance commitments, resulting in significant financial losses [6]. - Tibet Kangyu's actual net profit for 2023 was 15.67 million yuan, exceeding the commitment for that period, but it fell short in 2024 with only 16.78 million yuan against a commitment of 20 million yuan [4]. Group 2: Financial Performance - Huasun Technology's net profit has declined for three and a half consecutive years, with projections indicating a loss of 51.69 million to 61.69 million yuan in the upcoming period [1][8]. - The company's revenue figures from 2021 to 2024 show fluctuations, with a peak revenue of 955 million yuan in 2021, followed by declines in subsequent years [7]. - The expected net loss for the first half of 2025 is projected to be between 45 million and 55 million yuan, a significant drop from a profit of 911,000 yuan in the same period last year [8].

Group 1 - The board of directors of Chengdu Huasheng Technology Group Co., Ltd. held its 23rd meeting of the 13th session on August 1, 2025, with all 9 directors present, confirming compliance with relevant regulations [1][2] - The board approved the performance commitment completion report for Tibet Kangyu Pharmaceutical Co., Ltd., which reported a net profit of 16.78 million yuan for 2024, falling short of the promised 20 million yuan, leading to a cash compensation requirement from Tibet Wan'an Pharmaceutical Information Consulting Co., Ltd. [1][2] - The board approved the proposal to publicly transfer 51% of the equity of Tibet Kangyu, with a starting price based on asset evaluation at 63.78 million yuan, aiming to enhance the company's profitability and core competitiveness [2] Group 2 - The company scheduled its first extraordinary general meeting of shareholders for August 19, 2025, at 14:00, with all 9 votes in favor of the proposal [2]

Group 1 - The 16th meeting of the 13th Supervisory Board of Chengdu Huasheng Technology Group Co., Ltd. was held on August 1, 2025, via telecommunication, with all three supervisors present [1][2] - The Supervisory Board approved the performance commitment completion report for Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024, which showed a net profit of 16.7843 million yuan, falling short of the promised 20 million yuan, leading to a cash compensation requirement from Tibet Wan'an Pharmaceutical Information Consulting Co., Ltd. [1][2] - The Supervisory Board also approved the proposal to publicly transfer 51% of the equity of Tibet Kangyu, aligning with the company's future development plans and investment structure optimization [2]